[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

+1 (212) 332-3241

Email address

ADVANCE-1@axsome.com

Condition

Agitation in Patients With Dementia of the Alzheimer's Type,Agitation,Psychomotor,Alzheimer Disease

Treatment type

Interventional

Investigational product

AXS-05

Phase

Phase 2/Phase 3

Sponsor

Axsome Therapeutics, Inc.

ClinicalTrials.gov identifier

NCT03226522

Study number

AXS-05-AD-301

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
  1. Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria.
  2. Diagnosis of clinically signification agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation.
Exclusion criteria
  1. Patient has dementia predominantly of non-Alzheimer's type.
  2. Unable to comply with study procedures.
  3. Medically inappropriate for study participation in the opinion of the investigator.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site